Literature DB >> 8028387

Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study.

P O Daily1, J A Lamphere, W P Dembitsky, R M Adamson, N F Dans.   

Abstract

The prophylactic use of aprotinin has recently been reported to be associated with a significant decrease in blood loss in patients undergoing cardiopulmonary bypass procedures. One of the primary effects of aprotinin is prevention of plasmin degradation of platelet function. Because aprotinin is commercially unavailable in the United States at this time, we evaluated epsilon-aminocaproic acid with respect to decreased perioperative blood loss. We prospectively randomized 40 patients undergoing first-time coronary artery bypass grafting without prior sternotomy into two groups: one group (n = 21) received prophylactic and preincision epsilon-aminocaproic acid and the other (n = 19) received a placebo. No significant differences existed between patient groups with respect to age, body surface area, cardiopulmonary bypass time, and aortic crossclamp time. Cumulative blood loss at 4, 8, 12, and 24 hours after chest closure was significantly less in the epsilon-aminocaproic acid group (426 +/- 242 ml versus 634 +/- 224 ml, p = 0.002, at 12 hours). Only one patient receiving epsilon-aminocaproic acid was given blood or blood components compared to five patients in the placebo group (p < 0.02). D-dimers and fibrin split products were significantly less prevalent in the epsilon-aminocaproic acid group (at 4 hours: 0/20 versus 7/16, p < 0.002 and 5/20 versus 12/19, p < 0.05, respectively). None of the patients had a perioperative myocardial infarction or cerebrovascular accident. The prophylactic administration of epsilon-aminocaproic acid results in a significant decrease in blood loss in patients undergoing first-time coronary artery bypass grafting, and blood transfusion requirements are significantly less. It may be important to administer epsilon-aminocaproic acid before skin incision to be optimally effective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028387

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass.

Authors:  Y Uozaki; G Watanabe; K Kotou; K Ueyama; Y Doi; T Misaki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-05

2.  Aminocaproic acid used to control upper gastrointestinal bleeding in radiation gastritis.

Authors:  N Grover; A Johnson
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

Review 3.  Antifibrinolytic therapy in cardiac surgery.

Authors:  R H Chen; O H Frazier; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

Review 4.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  Limiting excessive postoperative blood transfusion after cardiac procedures. A review.

Authors:  V A Ferraris; S P Ferraris
Journal:  Tex Heart Inst J       Date:  1995

7.  Can local application of Tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial.

Authors:  Hosam Fawzy; Elsayed Elmistekawy; Daniel Bonneau; David Latter; Lee Errett
Journal:  J Cardiothorac Surg       Date:  2009-06-18       Impact factor: 1.637

8.  Does topical tranexamic acid reduce postcoronary artery bypass graft bleeding?

Authors:  Amir Mirmohammadsadeghi; Mohsen Mirmohammadsadeghi; Mahnaz Kheiri
Journal:  J Res Med Sci       Date:  2018-01-29       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.